Business Context and Reporting Period
Company: Diamedica Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 9, 2019
Reporting Period: Event date January 9, 2019
The Company, incorporated under the Canada Business Corporations Act, announced a voluntary delisting of its common shares from the TSX Venture Exchange (TSXV). This action follows the Company's initial public offering and subsequent listing on The Nasdaq Capital Market in December 2018.
Key Financial Metrics
This filing is a current report regarding a corporate governance and listing event. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Voluntary Delisting: The Board of Directors approved an application to delist from the TSXV effective January 9, 2019.
- Reasoning: Management determined that the financial and administrative costs of maintaining a dual listing (TSXV and Nasdaq) were not justified following the U.S. IPO.
- Trading Status: The delisting is expected to be effective at market close on January 18, 2019. Shares will continue to trade on The Nasdaq Capital Market under the symbol "DMAC".
Guidance, Outlook, and Risks
Management Commentary: The Company views the delisting as a cost-saving measure to eliminate the redundancy of dual listing fees and administrative burdens now that the primary listing is on Nasdaq.
Risks and Contingencies: The filing does not disclose specific financial risks, contingencies, or unusual items. The primary operational change is the cessation of trading on the TSXV.
Investor Verification Checklist
- Confirm the effective date of the TSXV delisting (expected January 18, 2019).
- Verify continued trading status on The Nasdaq Capital Market under symbol "DMAC".
- Review the attached press release (Exhibit 99.1) for additional details on the delisting process.
- Check subsequent filings for any impact on shareholder rights or proxy voting procedures resulting from the single-listing status.